| Literature DB >> 33685232 |
Jannike Salchow1, Barbara Koch1, Julia Mann1, Julia von Grundherr1, Simon Elmers1, Sarah Dwinger2, Gabriele Escherich3, Eik Vettorazzi4, Rüdiger Reer5, Marianne Sinn1, Freerk Baumann6, Carsten Bokemeyer1, Alexander Stein1, Wiebke Jensen1.
Abstract
OBJECTIVE: To explore whether a structured counselling-based intervention increases vigorous physical activity behaviour of adolescent and young adult cancer survivors.Entities:
Keywords: Cancer survivorship; adolescent and young adults; health behaviour; physical activity; quality of life
Mesh:
Year: 2021 PMID: 33685232 PMCID: PMC8273535 DOI: 10.1177/0269215521997974
Source DB: PubMed Journal: Clin Rehabil ISSN: 0269-2155 Impact factor: 3.477
Description of the counselling intervention based on the Transtheoretical Model.
| TTM stages | Description of TTM stage | Method of data collection | Counselling intervention by sport scientist |
|---|---|---|---|
| Stage 1: Precontemplation | Patients are not intending to take action in the foreseeable future because they are uninformed or underinformed about the consequences of their behaviour | Assessment of (vigorous) physical activity in week 0 | Documentation of (pre-existing) medical conditions (therapy- or disease-related).Informing patient about the benefits of regular physical activity, especially of vigorous intensity; discussing the personal health situation of the participant. Referring to current physical activity guidelines for cancer survivors. |
| Stage 2: Contemplation | Patients are intending to change in the next 6 months | Semi-structured interview (60 minutes) in week 0, phone calls in weeks 1 and 3 | Motivational talk regarding patients’ former and actual physical activity behaviour, recalling its positive impacts, as well as imagining future physical activity and possible positive impacts. |
| Stage 3: Preparation | Patients are intending to take action in the immediate future | Developing a specific, tailored personal exercise plan with the goal to adopt and maintain a physical activity behaviour. | |
| Evaluating local possibilities for activities and exercises close to the patients’ residence. | |||
| Stage 4: Action | Patients are making specific overt modifications in their life styles within the past 6 months | Assessment of (vigorous) physical activity after 12 and 52 weeks | Assistance for implementing the exercise plan. |
| Stage 5: Maintenance | Patients are working to prevent relapse | Considering a strategy to avoid a relapse to inactive behaviour. |
TTM: Transtheoretical Model.
Rate of participants with ⩾9 MET-hours/week of vigorous activity (primary outcome, intergroup comparison).
| Primary outcome | Timepoint | Intervention | Control | Odds ratio | |
|---|---|---|---|---|---|
| Rate ⩾9 MET hours/week | Post-intervention (week 12) | 23/32 | 19/29 | 1.4 (0.5–4.6) | 0.541 |
| Follow-up (week 52) | 17/28 | 10/19 | 1.2 (0.4–4.0) | 0.773 |
n: number of patients; CI: confidence interval; MET: metabolic equivalent.
Adjusted for baseline.
Course of physical activity behaviour assessed by the IPAQ (intergroup comparison).
| Secondary outcomes | Baseline (week 0) (AV ± SD) | Post-intervention (week 12) (AV ± SD) | Adjusted mean difference between groups in change from baseline (CI 95%) | Baseline vs post-intervention ( | Follow-up (week 52) (AV ± SD) | Adjusted mean difference between groups in change from baseline (CI 95%) | Baseline vs follow-up ( |
|---|---|---|---|---|---|---|---|
| Vigorous intensity days | |||||||
| Intervention | 1.6 ± 1.6 | 2.3 ± 1.4 | −0.3 (−1.2 to 0.5) | 0.413 | 2.0 ± 1.8 | −0.4 (−1.4 to 0.6) | 0.426 |
| Control | 1.9 ± 2.1 | 2.3 ± 1.9 | 1.8 ± 1.7 | ||||
| Vigorous intensity hours | |||||||
| Intervention | 0.8 ± 0.8 | 1.1 ± 0.8 | −0.1 (−0.6 to 0.4) | 0.689 | 1.2 ± 1.1 | −0.4 (−1.1 to 0.3) | 0.225 |
| Control | 1.1 ± 1.1 | 1.2 ± 1.1 | 1.1 ± 0.9 | ||||
| MET score vigorous intensity | |||||||
| Intervention | 19.5 ± 25.2 | 26.6 ± 24.6 | −3.1 (−17.6 to 11.3) | 0.664 | 30.0 ± 49.1 | −18.0 (−43.2 to 7.3) | 0.159 |
| Control | 29.8 ± 46.8 | 33.9 ± 42.1 | 23.7 ± 25.7 | ||||
| Moderate intensity days | |||||||
| Intervention | 2.8 ± 2.2 | 2.1 ± 1.7 | 0.4 (−1.0 to 1.8) | 0.564 | 2.9 ± 2.1 | 0.6 (−1.1 to 2.2) | 0.476 |
| Control | 2.8 ± 2.6 | 2.6 ± 2.5 | 3.5 ± 2.5 | ||||
| Moderate intensity hours | |||||||
| Intervention | 0.9 ± 0.9 | 0.8 ± 0.7 | 0.1 (−0.3 to 0.6) | 0.525 | 1.2 ± 1.1 | 0.0 (−0.6 to 0.7) | 0.907 |
| Control | 0.9 ± 1.0 | 0.9 ± 1.0 | 1.3 ± 1.1 | ||||
| MET score moderate intensity | |||||||
| Intervention | 12.1 ± 14.5 | 8.1 ± 10.2 | 3.6 (−4.9 to 12.1) | 0.398 | 17.8 ± 21.0 | −1.4 (−14.3 to 11.4) | 0.824 |
| Control | 16.9 ± 22.8 | 16.5 ± 25.4 | 21.6 ± 25.7 | ||||
| Walking days | |||||||
| Intervention | 5.2 ± 1.9 | 5.8 ± 1.5 | −0.3 (−1.2 to 0.6) | 0.495 | 5.6 ± 1.6 | −0.5 (−1.3 to 0.4) | 0.305 |
| Control | 5.6 ± 1.7 | 5.8 ± 1.7 | 5.4 ± 1.8 | ||||
| Walking hours | |||||||
| Intervention | 1.3 ± 0.9 | 1.3 ± 0.7 | 0.0 (−0.5 to 0.6) | 0.884 | 1.3 ± 0.9 | 0.1 (−0.4 to 0.7) | 0.687 |
| Control | 1.4 ± 1.0 | 1.5 ± 1.1 | 1.5 ± 0.9 | ||||
| MET score walking | |||||||
| Intervention | 24.1 ± 19.9 | 27.3 ± 16.9 | 2.6 (−9.5 to 14.7) | 0.669 | 25.2 ± 22.1 | 0.7 (−11.6 to 13.1) | 0.907 |
| Control | 27.0 ± 20.4 | 32.8 ± 25.3 | 28.9 ± 20.7 | ||||
| Sitting | |||||||
| Intervention | 6.4 ± 3.0 | 5.3 ± 2.6 | −0.1 (−1.4 to 1.1) | 0.820 | 5.7 ± 2.3 | 1.2 (−0.5 to 2.9) | 0.148 |
| Control | 6.6 ± 2.9 | 5.4 ± 2.8 | 6.4 ± 2.6 | ||||
| MET score total | |||||||
| Intervention | 55.2 ± 43.7 | 61.7 ± 29.4 | 6.5 (−18.0 to 31.0) | 0.598 | 73.7 ± 80.2 | −21.4 (−62.8 to 20.1) | 0.305 |
| Control | 75.3 ± 81.4 | 88.3 ± 80.2 | 78.5 ± 50.0 | ||||
AV: average value; SD: standard deviation; CI: confidence interval; IPAQ: International Physical Activity Questionnaire; MET: metabolic equivalent.
Figure 1.CONSORT flow diagram.
Patient characteristic of the total cohort (n = 89) and evaluable cohort (n = 69).
| Randomized | Evaluable | |||
|---|---|---|---|---|
| Total ( | Total ( | IG ( | CG ( | |
| Sex: female/male | 49/40 | 40/29 | 23/13 | 17/16 |
| Age (years; AV ± SD) | 24.1 ± 6.3 | 24.3 ± 6.5 | 23.4 ± 5.8 | 25.3 ± 7.2 |
| Female | 24.7 ± 6.5 | 24.6 ± 6.4 | 24.9 ± 6.5 | 24.2 ± 6.5 |
| Male | 23.4 ± 6.1 | 23.9 ± 6.7 | 20.8 ± 2.8 | 26.4 ± 7.9 |
| Age at diagnosis (years; AV ± SD) | 15.9 ± 9.0 | 16.3 ± 9.3 | 16.5 ± 5.8 | 16.0 ± 10.6 |
| Body mass index (kg/m2; AV ± SD) | 23.5 ± 5.1 | 23.5 ± 5.4 | 23.5 ± 5.2 | 23.6 ± 5.7 |
| Female | 22.5 ± 4.2 | 22.6 ± 4.5 | 23.2 ± 5.2 | 21.8 ± 3.2 |
| Male | 25.0 ± 5.7 | 24.9 ± 6.3 | 24.0 ± 5.5 | 25.7 ± 7.1 |
| Cancer diagnosis ( | ||||
| Solid tumours | 36 | 26 | 18 | 12 |
| Lymphoma | 35 | 30 | 14 | 12 |
| Leukaemia | 18 | 13 | 4 | 9 |
| Treatment at initial diagnosis ( | ||||
| Chemotherapy | 84 | 65 | 34 | 31 |
| Radio | 44 | 33 | 15 | 18 |
| Surgery | 33 | 27 | 17 | 10 |
| Time between end of therapy and study inclusion (years) | 7.3 ± 7.1 (6.0 weeks to 33.2 years) | 7.0 ± 7.3 (12.0 weeks to 33.1 years) | 6.1 ± 5.7 (12.0 weeks to 18.0 years) | 7.9 ± 8.8 (12.0 weeks to 33.1 years) |
n: number of patients; AV: average value; SD: standard deviation.